File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect?

TitleIntravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect?
Authors
Issue Date2011
PublisherBMJ Publishing Group. The Journal's web site is located at http://bjo.bmjjournals.com/
Citation
British Journal Of Ophthalmology, 2011, v. 95 n. 3, p. 391-395 How to Cite?
AbstractAims: To report the early development of epiretinal membranes (ERM) in eyes with retinal vein occlusions (RVO) treated with intravitreal bevacizumab and to describe possible mechanisms that may be involved in the growth and contraction of these lesions. Methods: Retrospective and interventional study that included 25 eyes of 25 patients with RVO (16 eyes with central retinal vein occlusion and nine eyes with branch retinal vein occlusion). After an initial 2.5 mg/0.1 ml intravitreal bevacizumab injection all patients were followed-up every 6 weeks. Re-treatments were based on visual acuity and optical coherence tomography findings. Results: Twenty-five eyes were treated with bevacizumab and followed for 8.3 (range 4.5-13.5) months. Four eyes developed an ERM within 6-7 weeks after the administration of bevacizumab. ERM was not associated with further deterioration of visual acuity or metamorphopsia in these patients. A rebound of macular oedema was observed in one patient with ERM and in two other patients. No other side effects were observed. Conclusions: Intravitreal bevacizumab may be associated with an early growth of ERM in eyes with RVO, although a causative relationship cannot be established. Future randomised clinical trials are necessary to determine the efficacy and safety profile of this novel therapy.
Persistent Identifierhttp://hdl.handle.net/10722/146313
ISSN
2015 Impact Factor: 3.036
2015 SCImago Journal Rankings: 1.873
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMarticorena, Jen_HK
dc.contributor.authorRomano, MRen_HK
dc.contributor.authorHeimann, Hen_HK
dc.contributor.authorStappler, Ten_HK
dc.contributor.authorGibran, Ken_HK
dc.contributor.authorGroenewald, Cen_HK
dc.contributor.authorPearce, Ien_HK
dc.contributor.authorWong, Den_HK
dc.date.accessioned2012-04-10T01:50:09Z-
dc.date.available2012-04-10T01:50:09Z-
dc.date.issued2011en_HK
dc.identifier.citationBritish Journal Of Ophthalmology, 2011, v. 95 n. 3, p. 391-395en_HK
dc.identifier.issn0007-1161en_HK
dc.identifier.urihttp://hdl.handle.net/10722/146313-
dc.description.abstractAims: To report the early development of epiretinal membranes (ERM) in eyes with retinal vein occlusions (RVO) treated with intravitreal bevacizumab and to describe possible mechanisms that may be involved in the growth and contraction of these lesions. Methods: Retrospective and interventional study that included 25 eyes of 25 patients with RVO (16 eyes with central retinal vein occlusion and nine eyes with branch retinal vein occlusion). After an initial 2.5 mg/0.1 ml intravitreal bevacizumab injection all patients were followed-up every 6 weeks. Re-treatments were based on visual acuity and optical coherence tomography findings. Results: Twenty-five eyes were treated with bevacizumab and followed for 8.3 (range 4.5-13.5) months. Four eyes developed an ERM within 6-7 weeks after the administration of bevacizumab. ERM was not associated with further deterioration of visual acuity or metamorphopsia in these patients. A rebound of macular oedema was observed in one patient with ERM and in two other patients. No other side effects were observed. Conclusions: Intravitreal bevacizumab may be associated with an early growth of ERM in eyes with RVO, although a causative relationship cannot be established. Future randomised clinical trials are necessary to determine the efficacy and safety profile of this novel therapy.en_HK
dc.languageengen_US
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://bjo.bmjjournals.com/en_HK
dc.relation.ispartofBritish Journal of Ophthalmologyen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAngiogenesis Inhibitors - Administration & Dosageen_US
dc.subject.meshAntibodies, Monoclonal - Administration & Dosageen_US
dc.subject.meshAntibodies, Monoclonal, Humanizeden_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshEpiretinal Membrane - Chemically Induced - Pathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIntravitreal Injectionsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRetinal Vein Occlusion - Complications - Drug Therapyen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshTomography, Optical Coherenceen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVascular Endothelial Growth Factor A - Antagonists & Inhibitorsen_US
dc.subject.meshVisual Acuity - Drug Effectsen_US
dc.titleIntravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect?en_HK
dc.typeArticleen_HK
dc.identifier.emailWong, D: shdwong@hku.hken_HK
dc.identifier.authorityWong, D=rp00516en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1136/bjo.2009.177287en_HK
dc.identifier.pmid20693565-
dc.identifier.scopuseid_2-s2.0-79952033566en_HK
dc.identifier.hkuros191511-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952033566&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume95en_HK
dc.identifier.issue3en_HK
dc.identifier.spage391en_HK
dc.identifier.epage395en_HK
dc.identifier.isiWOS:000287440400018-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMarticorena, J=14043688500en_HK
dc.identifier.scopusauthoridRomano, MR=35249070500en_HK
dc.identifier.scopusauthoridHeimann, H=7006780277en_HK
dc.identifier.scopusauthoridStappler, T=8563727800en_HK
dc.identifier.scopusauthoridGibran, K=37116831300en_HK
dc.identifier.scopusauthoridGroenewald, C=6601917086en_HK
dc.identifier.scopusauthoridPearce, I=35345778700en_HK
dc.identifier.scopusauthoridWong, D=7401536078en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats